Status:
COMPLETED
Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors
Lead Sponsor:
Biogen
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of the study is to see if daily and twice daily administration of BIIB021 is tolerated in patients with advanced solid tumors.
Detailed Description
Heat shock protein 90 (HSP90) inhibitors are anticipated to have clinical activity in solid tumors because Hsp90 is required for the folding, activation, and assembly of many proteins involved in canc...
Eligibility Criteria
Inclusion
- Subjects with histologically or cytologically confirmed solid tumor who have failed or refused standard therapies or for which no approved therapy is available.
- Age greater than or equal to 18 years at the time of informed consent. ECOG performance status of less than or equal to 2. Lab values consistent with adequate renal, hepatic, and bone marrow functions.
Exclusion
- Prior antitumor therapies, including prior experimental agents or approved antitumor small molecules and biologics within 28 days and all associated toxicities resolved to eligibility levels.
- Subjects with known brain metastases. Concurrent severe or uncontrolled medical disease. Must utilize effective contraception.
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT00618735
Start Date
February 1 2008
End Date
December 1 2010
Last Update
December 29 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Encinitas, California, United States, 92024
2
Research Site
Santa Monica, California, United States, 90404
3
Research Site
San Antonio, Texas, United States, 78229